Butyl Rubber Market to hit $5.62 Bn by 2025 –Insights on Competitive Strategies, Size, Share, Price Trend, Cost Margin, Potential Applications, Drivers and Future Opportunities: Adroit Market Research
/
Date01 Sep 2019
Email Print Friendly Share Dallas, Texas, Aug. 31, 2019 (GLOBE NEWSWIRE) — The “Global Butyl Rubber Market Size 2018, By Type (Regular Butyl rubber, Halobutyl... Read More →
Scandinavian Private Equity A/S : Salg endeligt gennemført og ekstraordinært udbytte
/
Date01 Sep 2019
Email Print Friendly Share Selskabsmeddelelse nr. 13 2019/20 København, den 1. september 2019 Salg endeligt gennemført og ekstraordinært udbytte Som tidligere kommunikeret i selskabsmeddelelse nr.... Read More →
Summit Financial Group, Inc. Announces Q3 2019 Dividend of $0.15 Per Share
/
Date01 Sep 2019
Email Print Friendly Share MOOREFIELD, W.V., Aug. 30, 2019 (GLOBE NEWSWIRE) — Summit Financial Group, Inc. (“Summit”) (NASDAQ: SMMF) today announces its Board of Directors... Read More →
InnerScope Hearing Technologies (OTCQB: INND) Reports Second Quarter 2019 Financial Results & Update on Key Revenue Growth Initiatives
/
Date01 Sep 2019
Email Print Friendly Share ROSEVILLE, Calif., Aug. 30, 2019 (GLOBE NEWSWIRE) — via OTC PR WIRE — InnerScope Hearing Technologies Inc. (OTCQB: INND) (“InnerScope”) a... Read More →
Davidson Kempner Capital Management LP : Form 8.3 – Allergan plc
/
Date01 Sep 2019
Email Print Friendly Share Ap19 FORM 8.3 IRISH TAKEOVER PANEL DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013 DEALINGS... Read More →
Solidium Oy:n puolivuosikatsaus 1.1.–30.6.2019 ja tilinpäätös:
/
Date01 Sep 2019
Email Print Friendly Share Solidium jatkoi 30.6.2019 päättyneellä tilikaudella aktiivisen omistajuuden strategiaansa. Yhtiön kymmenettä tilikautta leimasivat suuret vaihtelut tilikauden ensimmäisen ja toisen puoliskon välillä. Globaalissa... Read More →
MyoKardia Presents 36-week Data from PIONEER-OLE Study of Mavacamten at the European Society of Cardiology Congress 2019
/
Date01 Sep 2019
Email Print Friendly Share Durability of Mavacamten’s Safety and Efficacy Profile Demonstrated through Nine Months in this Study of Patients with Symptomatic, Obstructive HCM Statistically Significant Changes... Read More →